Back

Proteomic changes associated with vupanorsen therapy in TRANSLATE-TIMI-70

30 August 2026 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Lipid profiling and coronary artery disease (2) Lipids ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Rishi Bansal

McMaster University, Hamilton (Canada)

5 More presentations in this session

Presentation thumbnail
Lipoprotein(a) levels in children with genetically confirmed heterozygous familial hypercholesterolaemia
Miss K. Martins Barreto Borges (Sao Paulo, BR)
Abstract Slides
Presentation thumbnail
Association between remnant cholesterol at the age of 30 and all-cause mortality during long-term follow-up: a cohort study
Doctor E. Aaseth (Oslo, NO)
Abstract Slides
Presentation thumbnail
Clinical impact of combined LDL cholesterol and remnant cholesterol phenotypes after coronary revascularization: insights from a nationwide cohort
Doctor J. Lee (Wonju, KR)
Abstract Slides
Presentation thumbnail
Small dense LDL, clinical characteristics and survival - an analysis of LIPIDOGRAM2004-2015 cohort studies
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
Real-world prediagnosis lipid management in parents identified through child-initiated reverse cascade screening for familial hypercholesterolaemia
Doctor R. Tani (Kagawa, JP)
Abstract Slides

Access the full session

Session thumbnail
Lipid profiling and coronary artery disease (2)

The Event

Event poster

ESC Congress 2026

30 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Proteomics profiling reveals signaling pathways associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy
28 August 2022
thumbnail
Congress Presentation
RNA interference targeting apolipoprotein C-III with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-III deficiency
31 August 2020
thumbnail
Congress Presentation
Multi-marker biomarker panel, adverse cardiovascular and kidney outcomes, and response to canagliflozin in the CANVAS Program
29 June 2021
thumbnail
Congress Presentation
GLP1-RA associated with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources